Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Shang Q, Saumoy M, Holst JJ, Salen G, Xu G
At the beginning of his recent Vanderbilt Discovery Lecture on glucagon-like peptide-1 (GLP-1) receptor agonists, Daniel Drucker, MD, joked that the title for his presentation could be What I still dont understand about how GLP-1 works. Drucker is a pioneering scientist whose research contributed to the development of the blockbuster GLP-1 medicines used to treat diabetes and obesity
A., Fadzeyeva, E
IS IGF-1LR3 SAFE
P Peeling, MJ Binnie, et al